SEC Form 4 · accession 0001104659-19-005908
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C King
Officer — Chief Commercial Officer
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 7:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $21.00 | Feb 1, 2019 | A | 107,000 | A | — | Feb 1, 2029 | Common Stock | 107,000 | 107,000 | D |
Explanation of responses
- F1These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date; provided that none of the shares of common stock underlying the option shall vest prior to the first anniversary of the date of the commencement of such individual's employment (the "First Anniversary") and the shares of common stock that would have vested but for this proviso shall vest on the First Anniversary (with any remaining shares vesting in accordance with the schedule otherwise set forth herein), subject to the terms set forth in the applicable equity agreement.